S&P 500
5.187,70 +6,96 (+0,13%) Nasdaq
16.332,56 -16,69 (-0,10%) NIKKEI 225
38.835,10 0,00 (0,00%) Dólar/Euro
1,0752 -0,0007 (-0,06%) Petróleo Brent
83,05 -0,11 (-0,13%) Bitcoin EUR
58.027,66 -792,11 (-1,35%)
Provectus Biopharmaceuticals, Inc. (PVCT)
Provectus Biopharmaceuticals, Inc.
800 South Gay Street
Suite 1610
Knoxville, TN 37929
United States
866 594 5999
https://www.provectusbio.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 4
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Dominic Rodrigues C.F.A. | President & Vice Chairman of the Board | 75k | N/A | 1969 |
| Dr. Eric A. Wachter Ph.D. | Co-Founder & CTO | 253,25k | N/A | 1963 |
Descripción
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis. It is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, the company develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections, as well as vertebrate development, wound healing, and tissue regrowth. It has collaboration agreement with Bascom Palmer Eye Institute; and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.
Gobierno corporativo
El ISS Governance QualityScore de Provectus Biopharmaceuticals, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
